[go: up one dir, main page]

WO2025104706A3 - Modulateurs de récepteurs mas et mrgd à petites molécules - Google Patents

Modulateurs de récepteurs mas et mrgd à petites molécules

Info

Publication number
WO2025104706A3
WO2025104706A3 PCT/IB2024/061441 IB2024061441W WO2025104706A3 WO 2025104706 A3 WO2025104706 A3 WO 2025104706A3 IB 2024061441 W IB2024061441 W IB 2024061441W WO 2025104706 A3 WO2025104706 A3 WO 2025104706A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrgd
mas
small molecule
receptors
molecule modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/061441
Other languages
English (en)
Other versions
WO2025104706A2 (fr
Inventor
Thomas Walther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xitra Therapeutics GmbH
Original Assignee
Xitra Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xitra Therapeutics GmbH filed Critical Xitra Therapeutics GmbH
Publication of WO2025104706A2 publication Critical patent/WO2025104706A2/fr
Publication of WO2025104706A3 publication Critical patent/WO2025104706A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des modulateurs à petites molécules des récepteurs couplés à la protéine G Mas et MrgD, y compris des composés de formules A (par exemple, formule (I)-(X) et (B)), et des formes pharmaceutiquement acceptables de ceux-ci. L'invention concerne également des compositions (par exemple, des compositions pharmaceutiques) comprenant des composés et des sels pharmaceutiquement acceptables décrits ici, ainsi que des utilisations des composés, des formes pharmaceutiquement acceptables de ceux-ci, et des compositions dans des méthodes de traitement de maladies et de troubles, y compris ceux décrits dans la description.
PCT/IB2024/061441 2023-11-15 2024-11-15 Modulateurs de récepteurs mas et mrgd à petites molécules Pending WO2025104706A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363599411P 2023-11-15 2023-11-15
US63/599,411 2023-11-15

Publications (2)

Publication Number Publication Date
WO2025104706A2 WO2025104706A2 (fr) 2025-05-22
WO2025104706A3 true WO2025104706A3 (fr) 2025-07-17

Family

ID=93799702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/061441 Pending WO2025104706A2 (fr) 2023-11-15 2024-11-15 Modulateurs de récepteurs mas et mrgd à petites molécules

Country Status (2)

Country Link
TW (1) TW202527908A (fr)
WO (1) WO2025104706A2 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0314835A (ja) * 1989-06-12 1991-01-23 New Japan Chem Co Ltd 芳香族環状ポリイミドの製造方法
WO2001082924A1 (fr) * 2000-05-02 2001-11-08 Smithkline Beecham Corporation Inhibiteurs du transport de phosphate
WO2001092273A2 (fr) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Derives d'acide benzenedicarboxylique
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
WO2005000793A1 (fr) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. Derive d'acide cycloalkylcarboxylique substitue en position 2
US20070148185A1 (en) * 2005-10-14 2007-06-28 Dharmender Rathore Novel therapeutic target for protozoal diseases
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition
US20120283215A1 (en) * 2009-09-15 2012-11-08 The United States Of America, As Represented By The Secretary, Department Of Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
WO2014151413A2 (fr) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions pharmaceutique d'un agent de ciblage de fkbp52
WO2014182673A1 (fr) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur mas couplé à la protéine g et traitement de troubles apparentés
IN202111031316A (fr) * 2021-07-13 2021-07-30

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
AU755225B2 (en) 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0314835A (ja) * 1989-06-12 1991-01-23 New Japan Chem Co Ltd 芳香族環状ポリイミドの製造方法
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
WO2001082924A1 (fr) * 2000-05-02 2001-11-08 Smithkline Beecham Corporation Inhibiteurs du transport de phosphate
WO2001092273A2 (fr) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Derives d'acide benzenedicarboxylique
WO2005000793A1 (fr) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. Derive d'acide cycloalkylcarboxylique substitue en position 2
US20070148185A1 (en) * 2005-10-14 2007-06-28 Dharmender Rathore Novel therapeutic target for protozoal diseases
US20120283215A1 (en) * 2009-09-15 2012-11-08 The United States Of America, As Represented By The Secretary, Department Of Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition
WO2014151413A2 (fr) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions pharmaceutique d'un agent de ciblage de fkbp52
WO2014182673A1 (fr) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur mas couplé à la protéine g et traitement de troubles apparentés
IN202111031316A (fr) * 2021-07-13 2021-07-30

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "129025-07-6", STN REGISTRY - CA, 24 August 1990 (1990-08-24), pages 1 - 1, XP093247684, Retrieved from the Internet <URL:https://www.stn.org/> *
ANONYMOUS: "2309345-41-1", STN REGISTRY - CHEMICAL LIBRARY SUPPLIER: AURORA FINE CHEMICALS, 16 May 2019 (2019-05-16), pages 1 - 1, XP093247686, Retrieved from the Internet <URL:https://www.stn.org/> *
ANONYMOUS: "2679949-59-6", STN REGISTRY - CHEMICAL CATALOG, 24 August 2021 (2021-08-24), pages 1 - 1, XP093247678, Retrieved from the Internet <URL:https://www.stn.org/> *
ANONYMOUS: "2861186-44-7", STN REGISTRY - CHEMICAL CATALOG SUPPLIER: AURORA FINE CHEMICALS LLC, 28 November 2022 (2022-11-28), pages 1 - 1, XP093247681, Retrieved from the Internet <URL:https://www.stn.org/> *
ANONYMOUS: "2865023-61-4", STN REGISTRY- CHEMICAL CATALOG SUPPLIER: AURORA FINE CHEMICALS LLC, 5 December 2022 (2022-12-05), pages 1 - 1, XP093247683, Retrieved from the Internet <URL:https://www.stn.org/> *
C. M. NISWENDER ET AL: "Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4", MOLECULAR PHARMACOLOGY, vol. 74, no. 5, 1 January 2008 (2008-01-01), pages 1345 - 1358, XP055057175, ISSN: 0026-895X, DOI: 10.1124/mol.108.049551 *
XIAOJUAN YU ET AL: "Discovery of novel inhibitors for human farnesyltransferase (hFTase) via structure-based virtual screening", MEDCHEMCOMM, vol. 4, no. 6, 1 January 2013 (2013-01-01), United Kingdom, pages 962, XP055720786, ISSN: 2040-2503, DOI: 10.1039/c3md00058c *
ZHANG PEI ET AL: "Metabolic Syndrome: An Important Risk Factor for Parkinson's Disease", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2014, 14 May 2014 (2014-05-14), US, pages 1 - 7, XP093247962, ISSN: 1942-0900, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/omcl/2014/729194.pdf> DOI: 10.1155/2014/729194 *

Also Published As

Publication number Publication date
TW202527908A (zh) 2025-07-16
WO2025104706A2 (fr) 2025-05-22

Similar Documents

Publication Publication Date Title
DE60206408T2 (de) Omega-zykloalkyl 17-heteroaryl prostaglandin-e2-analoga als ep2-rezeptoragonisten
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
CA2360313A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
ATE386725T1 (de) Heterocyclylverbindungen
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
NO20040881L (no) Orale antidiabetes midler.
ATE424822T1 (de) Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
DK0808303T3 (da) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
SE0102055D0 (sv) New Compounds
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
WO2025104706A3 (fr) Modulateurs de récepteurs mas et mrgd à petites molécules
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24818068

Country of ref document: EP

Kind code of ref document: A2